F-group (family)
219.1.1.27 Menin
Ligands and drugs
71
Member domains
52
with ligand contacts (≤ 4 Å)
73.2% of members
47
with DrugDomain annotations
66.2% of members
38
with a DrugBank compound
53.5% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 219.1.1.27 belongs to X-group 219 Cysteine proteinases-like, which binds 9.6 ligand superclasses per 20 proteins, broader than 89% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB18515 | OQ4 | Revumenib | 4 |
| DB01833 | GGB | Canavanine | 2 |
| DB02659 | CHD | Cholic Acid | 2 |
| DB04343 | GLV | Glyoxylic acid | 2 |
| DB02726 | PGA | 2-Phosphoglycolic Acid | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| 7IX | (1R,2S,4R)-4-[[4-(5,6-dimethoxypyridazin-3-yl)phenyl]methylamino]-2-[methyl-[6-[2,2,2-tris(fluoranyl)ethyl]thieno[2,3-d]pyrimidin-4-yl]amino]cyclopentan-1-ol | 4 |
| 7PR | praseodymium triacetate | 4 |
| 9N6 | N-ethyl-5-fluoro-2-{[5-(2-{(3R)-6-[(2-methoxyethyl)(methyl)amino]-2-methylhexan-3-yl}-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl]oxy}-N-(propan-2-yl)benzamide | 4 |
| OQ4 | 2-({4-[7-({(1r,4r)-4-[(ethanesulfonyl)amino]cyclohexyl}methyl)-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl}oxy)-N-ethyl-5-fluoro-N-(propan-2-yl)benzamide | 4 |
| 0BR | (4beta,8alpha,9R)-6'-methoxy-10,11-dihydrocinchonan-9-ol | 2 |
| CHD | CHOLIC ACID | 2 |
| GGB | L-CANAVANINE | 2 |
| GLV | GLYOXYLIC ACID | 2 |
| MGmetal | MAGNESIUM ION | 2 |
| OP4 | 5-fluoro-2-({4-[7-({trans-4-[(methylsulfonyl)amino]cyclohexyl}methyl)-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl}oxy)-N,N-di(propan-2-yl)benzamide | 2 |
| UNX | UNKNOWN ATOM OR ION | 2 |
| 0RO | 4-[4-(5,5-dimethyl-4,5-dihydro-1,3-thiazol-2-yl)piperazin-1-yl]-6-propylthieno[2,3-d]pyrimidine | 1 |
| 0RT | 4-[4-(5,5-dimethyl-4,5-dihydro-1,3-thiazol-2-yl)piperazin-1-yl]-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidine | 1 |
| 2S6 | 4-(3-{4-[(R)-cyclopentyl(hydroxy)phenylmethyl]piperidin-1-yl}propoxy)benzonitrile | 1 |
| 2S7 | 4-(3-{4-[(S)-cyclopentyl(hydroxy)pyridin-2-ylmethyl]piperidin-1-yl}propoxy)benzonitrile | 1 |
| 2S9 | 4-(3-{4-[(R)-cyclopentyl(3-fluorophenyl)hydroxymethyl]piperidin-1-yl}propoxy)benzonitrile | 1 |
| 2SE | 4-(3-{4-[(S)-cyclopentyl(hydroxy)pyridin-2-ylmethyl]piperidin-1-yl}propoxy)benzenesulfonamide | 1 |
| 2SF | 4-(3-{4-[(R)-amino(cyclopentyl)phenylmethyl]piperidin-1-yl}propoxy)benzonitrile | 1 |
| 2VK | 4-(3-{4-[(S)-cyclopentyl(hydroxy)phenylmethyl]piperidin-1-yl}propoxy)benzonitrile | 1 |
| 3XW | 4-methyl-1-(1H-pyrazol-4-ylmethyl)-5-[(4-{[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino}piperidin-1-yl)methyl]-1H-indole-2-carbonitrile | 1 |